Clinical Trial

Rocklatan vs Latanoprost Post-DSLT

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This is a randomized, double-masked, single-site, prospective, contralateral eye study designed to evaluate the outcomes of Direct Selective Laser Trabeculoplasty (DSLT) followed by the addition of combination netarsudil and latanoprost (Rocklatan) versus latanoprost monotherapy. The study will be conducted at one investigational site. The primary endpoint is the change in mean diurnal intraocular pressure (IOP) from baseline (post DSLT and post washout) at visit 3 between the two groups. Secondary endpoints include the change in mean IOP from baseline at each timepoint (8am, 12pm, 4pm) at visit 3 between groups, and the mean percentage decrease in IOP from baseline for each group. Assessments will be conducted at three key visits: Visit 1 (Screening Phase and DSLT Procedure on Day 0), Visit 2 (Baseline Visit post washout at Week 8), and Visit 3 (Follow-Up Visit 1 at Week 12). Each visit will include specific examinations and measurements such as visual field and OCT imaging, diurnal IOP measurements, and documentation of adverse events.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-23
Trial Details
NCT Number NCT07465913
Lead Sponsor Eye Centers of Southeast Texas
Collaborators: Sengi
Conditions Glaucoma
Enrollment 36 participants
Start Date 2026-05-14
Primary Completion 2027-05-06 (estimated)
Study Completion 2027-05-06 (estimated)
Updated on ClinicalTrials.gov 2026-05-22